Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China · Delayed Price · Currency is CNY 19.95
-2.05 (-9.32%)
Aug 21, 2026, 3:00 PM CST
Aurisco Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 688.91 | 792.37 | 769.44 | 545.84 | 391.74 | 444.61 |
Trading Asset Securities | 228.26 | 161.52 | 299.83 | - | - | - |
Cash & Short-Term Investments | 917.17 | 953.9 | 1,069 | 545.84 | 391.74 | 444.61 |
Cash Growth | -7.17% | -10.79% | 95.89% | 39.34% | -11.89% | -21.18% |
Accounts Receivable | 420.66 | 434.32 | 350.87 | 290.78 | 222.11 | 140.72 |
Other Receivables | 3.86 | 4.02 | 4.23 | 8.31 | 3.9 | 6.19 |
Receivables | 424.52 | 438.34 | 355.11 | 299.09 | 226.01 | 146.91 |
Inventory | 661.59 | 644.88 | 589.72 | 509.8 | 444.94 | 326.8 |
Prepaid Expenses | - | - | - | - | 0.17 | - |
Other Current Assets | 23.09 | 19.48 | 32.7 | 11.31 | 25.5 | 21.48 |
Total Current Assets | 2,026 | 2,057 | 2,047 | 1,366 | 1,088 | 939.8 |
Property, Plant & Equipment | 1,833 | 1,779 | 1,497 | 878.33 | 674.18 | 593.26 |
Long-Term Investments | 171.36 | 166.36 | 133.47 | 79.3 | 55.3 | 15.3 |
Other Intangible Assets | 159.31 | 160.37 | 161.46 | 121.4 | 122.71 | 40.42 |
Long-Term Deferred Tax Assets | 23.61 | 22.54 | 15.78 | 14.29 | 15.24 | 8.56 |
Long-Term Deferred Charges | 4.17 | 4.72 | 5.32 | 6.91 | 11.37 | - |
Other Long-Term Assets | 35.71 | 32.03 | 17.41 | 108.35 | 68.14 | 124.09 |
Total Assets | 4,254 | 4,222 | 3,877 | 2,575 | 2,035 | 1,721 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 338.35 | 297.19 | 297.39 | 242.53 | 102.43 | 128.2 |
Accrued Expenses | 38.7 | 138.94 | 121.64 | 92.89 | 51.95 | 40.89 |
Short-Term Debt | 20.02 | 20.02 | 20.02 | 40.04 | 30 | - |
Current Portion of Long-Term Debt | - | - | - | - | 1.3 | - |
Current Portion of Leases | - | 5.87 | 5.64 | 5.14 | 4.93 | 4.06 |
Current Income Taxes Payable | 21.1 | 26.02 | 25 | 16.64 | 12.85 | 8.61 |
Current Unearned Revenue | 8.21 | 3.06 | 6.6 | 22.25 | 0.98 | 8.96 |
Other Current Liabilities | 53.61 | 29.96 | 55.74 | 81.53 | 117.75 | 2.36 |
Total Current Liabilities | 479.98 | 521.06 | 532.04 | 501.02 | 322.17 | 193.08 |
Long-Term Debt | 925.65 | 917.96 | 907.09 | 60.46 | 4.22 | - |
Long-Term Leases | 23.83 | 15.12 | 15.1 | 11.24 | 12.23 | 13.91 |
Long-Term Unearned Revenue | 102.98 | 105.91 | 91.57 | 34.02 | 7.69 | 4.53 |
Long-Term Deferred Tax Liabilities | 3.12 | 4.38 | 0.1 | 0.28 | 4.81 | 1.92 |
Total Liabilities | 1,536 | 1,564 | 1,546 | 607.03 | 351.13 | 213.44 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 406.18 | 406.2 | 406.2 | 406.2 | 406.2 | 401 |
Additional Paid-In Capital | 613.86 | 613.96 | 606.5 | 584.93 | 553.36 | 491.73 |
Retained Earnings | 1,637 | 1,573 | 1,241 | 975.92 | 751.49 | 592.71 |
Treasury Stock | -60.03 | -55.26 | -22.86 | -45.72 | -57.15 | - |
Comprehensive Income & Other | 121.3 | 119.51 | 100.34 | 46.25 | 22.28 | 20.8 |
Total Common Equity | 2,718 | 2,658 | 2,332 | 1,968 | 1,676 | 1,506 |
Minority Interest | - | - | - | - | 7.99 | 1.75 |
Shareholders' Equity | 2,718 | 2,658 | 2,332 | 1,968 | 1,684 | 1,508 |
Total Liabilities & Equity | 4,254 | 4,222 | 3,877 | 2,575 | 2,035 | 1,721 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 969.5 | 958.97 | 947.85 | 116.88 | 52.69 | 17.97 |
Net Cash (Debt) | -52.32 | -5.07 | 121.42 | 428.95 | 339.05 | 426.64 |
Net Cash Growth | - | - | -71.69% | 26.52% | -20.53% | -24.37% |
Net Cash Per Share | -0.13 | -0.01 | 0.30 | 1.05 | 0.84 | 1.06 |
Filing Date Shares Outstanding | 403.41 | 403.41 | 406.2 | 406.2 | 406.2 | 401 |
Total Common Shares Outstanding | 403.41 | 406.2 | 406.2 | 406.2 | 406.2 | 401 |
Working Capital | 1,546 | 1,536 | 1,515 | 865.02 | 766.19 | 746.72 |
Book Value Per Share | 6.74 | 6.54 | 5.74 | 4.84 | 4.13 | 3.76 |
Tangible Book Value | 2,559 | 2,497 | 2,170 | 1,846 | 1,553 | 1,466 |
Tangible Book Value Per Share | 6.34 | 6.15 | 5.34 | 4.55 | 3.82 | 3.66 |
Buildings | - | 621.3 | 291.81 | 291.85 | 289.74 | 283.37 |
Machinery | - | 1,446 | 735.79 | 640.39 | 587.27 | 485.03 |
Construction In Progress | - | 217.39 | 869.74 | 280.64 | 79.93 | 47.83 |